Supernus Pharmaceuticals

SUPN

Market cap $2.76B

48.16 USD

-0.90

1.83%

At close Updated Jan 30, 4:00 PM EST

Pre-market

After hours

48.16

0.00

1 day

-1.83%

5 days

0.19%

1 month

-3.47%

3 months

-14.76%

6 months

43.5%

Year to date

-2.65%

1 year

24.48%

5 years

60.48%

10 years

327.33%

About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Employees: 674

Healthcare Drug Manufacturers - Specialty & Generic